S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Most profitable less than $5 stock in the world? (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Italy's Lake Garda shrinks to near-historic low amid drought
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
Germans urged to cap heat in offices this winter to save gas
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Most profitable less than $5 stock in the world? (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Italy's Lake Garda shrinks to near-historic low amid drought
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
Germans urged to cap heat in offices this winter to save gas
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Most profitable less than $5 stock in the world? (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Italy's Lake Garda shrinks to near-historic low amid drought
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
Germans urged to cap heat in offices this winter to save gas
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Most profitable less than $5 stock in the world? (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Italy's Lake Garda shrinks to near-historic low amid drought
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
Germans urged to cap heat in offices this winter to save gas
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
NASDAQ:DXCM

DexCom - DXCM Stock Forecast, Price & News

$89.83
+1.59 (+1.80%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$87.60
$89.90
50-Day Range
$67.99
$91.40
52-Week Range
$66.89
$164.86
Volume
1.91 million shs
Average Volume
3.15 million shs
Market Capitalization
$35.27 billion
P/E Ratio
187.15
Dividend Yield
N/A
Price Target
$112.30

DexCom MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.93 Rating Score
Upside/​Downside
25.0% Upside
$112.30 Price Target
Short Interest
Healthy
3.09% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.76
Upright™ Environmental Score
News Sentiment
0.37mentions of DexCom in the last 14 days
Based on 18 Articles This Week
Insider Trading
Selling Shares
$410,644 Sold Last Quarter
Proj. Earnings Growth
40.51%
From $0.79 to $1.11 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.03 out of 5 stars

Medical Sector

24th out of 1,135 stocks

Surgical & Medical Instruments Industry

3rd out of 114 stocks

DXCM stock logo

About DexCom (NASDAQ:DXCM) Stock

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

DexCom Stock Performance

DXCM Stock traded up $1.59 during mid-day trading on Friday, hitting $89.83. 1,914,913 shares of the company were exchanged, compared to its average volume of 3,152,051. The business has a 50 day simple moving average of $78.92 and a 200-day simple moving average of $94.89. The company has a current ratio of 4.72, a quick ratio of 4.30 and a debt-to-equity ratio of 0.87. The stock has a market capitalization of $35.27 billion, a PE ratio of 187.15, a price-to-earnings-growth ratio of 3.53 and a beta of 1.03. DexCom has a 1-year low of $66.89 and a 1-year high of $164.86.

DexCom (NASDAQ:DXCM - Get Rating) last issued its quarterly earnings data on Thursday, July 28th. The medical device company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.19 by ($0.02). The company had revenue of $696.20 million for the quarter, compared to analyst estimates of $709.33 million. DexCom had a return on equity of 11.79% and a net margin of 7.47%. The company's revenue was up 17.0% on a year-over-year basis. During the same quarter last year, the business earned $0.19 earnings per share. On average, equities analysts forecast that DexCom will post 0.79 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently commented on DXCM. Sanford C. Bernstein began coverage on shares of DexCom in a research note on Friday, July 15th. They set an "outperform" rating and a $105.00 price objective for the company. Cowen restated a "buy" rating and set a $85.00 price objective on shares of DexCom in a research note on Friday, July 29th. SVB Leerink reduced their price objective on shares of DexCom from $141.25 to $125.00 in a research note on Friday, April 29th. Wells Fargo & Company reduced their price objective on shares of DexCom from $144.00 to $102.00 in a research note on Friday, July 29th. Finally, Robert W. Baird cut their target price on shares of DexCom from $115.00 to $97.00 in a research note on Friday, July 29th. Two research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. Based on data from MarketBeat, DexCom presently has an average rating of "Moderate Buy" and an average target price of $115.23.

Insider Transactions at DexCom

In other news, Director Steven Robert Pacelli sold 1,000 shares of the firm's stock in a transaction that occurred on Thursday, June 23rd. The shares were sold at an average price of $72.55, for a total transaction of $72,550.00. Following the transaction, the director now directly owns 139,700 shares of the company's stock, valued at $10,135,235. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director Steven Robert Pacelli sold 1,000 shares of the firm's stock in a transaction that occurred on Thursday, June 23rd. The shares were sold at an average price of $72.55, for a total transaction of $72,550.00. Following the transaction, the director now directly owns 139,700 shares of the company's stock, valued at $10,135,235. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Jereme M. Sylvain sold 600 shares of the firm's stock in a transaction that occurred on Monday, June 6th. The stock was sold at an average price of $301.57, for a total transaction of $180,942.00. Following the transaction, the chief financial officer now directly owns 17,408 shares in the company, valued at $5,249,730.56. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 2,850 shares of company stock valued at $410,645. 0.41% of the stock is currently owned by company insiders.

Receive DXCM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DexCom and its competitors with MarketBeat's FREE daily newsletter.

DXCM Stock News Headlines

2 Growth Stocks That Just Hit Setbacks: Are They Buys?
DexCom (NASDAQ:DXCM) Stock Rating Reaffirmed by Cowen
Oppenheimer Cuts DexCom (NASDAQ:DXCM) Price Target to $105.00
DexCom (NASDAQ:DXCM) PT Lowered to $100.00
DexCom (NASDAQ:DXCM) Shares Gap Down After Earnings Miss
Why DexCom Stock Is Falling Today
See More Headlines
Receive DXCM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DexCom and its competitors with MarketBeat's FREE daily newsletter.

DXCM Company Calendar

Last Earnings
7/28/2022
Today
8/13/2022
Next Earnings (Estimated)
10/27/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:DXCM
CUSIP
25213110
Employees
7,000
Year Founded
1999

Price Target and Rating

Average Stock Price Forecast
$112.30
High Stock Price Forecast
$163.75
Low Stock Price Forecast
$83.00
Forecasted Upside/Downside
+25.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.93
Research Coverage
14 Analysts

Profitability

Net Income
$154.70 million
Pretax Margin
5.49%

Debt

Sales & Book Value

Annual Sales
$2.45 billion
Cash Flow
$0.97 per share
Book Value
$5.75 per share

Miscellaneous

Free Float
390,972,000
Market Cap
$35.27 billion
Optionable
Optionable
Beta
1.03

Social Links















DXCM Stock - Frequently Asked Questions

Should I buy or sell DexCom stock right now?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last twelve months. There are currently 1 hold rating and 13 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" DXCM shares.
View DXCM analyst ratings
or view top-rated stocks.

What is DexCom's stock price forecast for 2022?

14 brokers have issued 1 year price targets for DexCom's stock. Their DXCM share price forecasts range from $83.00 to $163.75. On average, they predict the company's stock price to reach $112.30 in the next year. This suggests a possible upside of 25.0% from the stock's current price.
View analysts price targets for DXCM
or view top-rated stocks among Wall Street analysts.

How have DXCM shares performed in 2022?

DexCom's stock was trading at $134.2375 at the start of the year. Since then, DXCM stock has decreased by 33.1% and is now trading at $89.83.
View the best growth stocks for 2022 here
.

When is DexCom's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 27th 2022.
View our DXCM earnings forecast
.

How were DexCom's earnings last quarter?

DexCom, Inc. (NASDAQ:DXCM) released its quarterly earnings results on Thursday, July, 28th. The medical device company reported $0.17 EPS for the quarter, missing analysts' consensus estimates of $0.19 by $0.02. The medical device company had revenue of $696.20 million for the quarter, compared to analyst estimates of $709.33 million. DexCom had a trailing twelve-month return on equity of 11.79% and a net margin of 7.47%. The company's quarterly revenue was up 17.0% on a year-over-year basis. During the same period in the prior year, the firm posted $0.19 EPS.
Read the conference call transcript
.

When did DexCom's stock split?

DexCom's stock split before market open on Friday, June 10th 2022. The 4-1 split was announced on Friday, March 25th 2022. The newly minted shares were issued to shareholders after the market closes on Thursday, June 9th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split.

What guidance has DexCom issued on next quarter's earnings?

DexCom issued an update on its FY 2022 earnings guidance on Thursday, August, 4th. The company provided EPS guidance of for the period. The company issued revenue guidance of $2.86 billion-$2.91 billion, compared to the consensus revenue estimate of $2.92 billion.

What is Kevin Sayer's approval rating as DexCom's CEO?

347 employees have rated DexCom Chief Executive Officer Kevin Sayer on Glassdoor.com. Kevin Sayer has an approval rating of 88% among the company's employees.

What other stocks do shareholders of DexCom own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DexCom investors own include NVIDIA (NVDA), PayPal (PYPL), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), Salesforce (CRM), ServiceNow (NOW), Walt Disney (DIS), Trade Desk (TTD) and Shopify (SHOP).

What is DexCom's stock symbol?

DexCom trades on the NASDAQ under the ticker symbol "DXCM."

Who are DexCom's major shareholders?

DexCom's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (4.61%), Sands Capital Management LLC (4.56%), Jennison Associates LLC (2.18%), Clearbridge Investments LLC (1.45%), Northern Trust Corp (0.99%) and Brown Advisory Inc. (0.87%). Insiders that own company stock include Andrew K Balo, Andrew K Balo, Barbara Kahn, Barry J Regan, Bridgette P Heller, Chad Patterson, Donald Abbey, Heather S Ace, Jacob Steven Leach, Jay S Skyler, Jeffrey Moy, Jereme M Sylvain, Jereme M Sylvain, Kevin R Sayer, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Paul R Flynn, Quentin S Blackford, Richard Alexander Collins, Richard Doubleday, Sadie Stern, Shelly Ramasamy Selvaraj, Steven R Altman, Steven Robert Pacelli and Sumi Shrishrimal.
View institutional ownership trends
.

How do I buy shares of DexCom?

Shares of DXCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is DexCom's stock price today?

One share of DXCM stock can currently be purchased for approximately $89.83.

How much money does DexCom make?

DexCom (NASDAQ:DXCM) has a market capitalization of $35.27 billion and generates $2.45 billion in revenue each year. The medical device company earns $154.70 million in net income (profit) each year or $0.48 on an earnings per share basis.

How many employees does DexCom have?

The company employs 7,000 workers across the globe.

Does DexCom have any subsidiaries?

The following companies are subsidiares of DexCom: DexCapital LLC, DexCom (Canada) Inc., DexCom (UK) Distribution Ltd., DexCom (UK) Intermediate Holdings Ltd., DexCom (UK) Ltd., DexCom Asia Pacific Operations PTE Ltd., DexCom Canada Co, DexCom Deutschland GmbH, DexCom International Ltd., DexCom Kommanditbolag, DexCom Operating Ltd., DexCom Philippines Inc, DexCom Suisse GmbH, Nintamed Handels GmbH, SweetSpot Diabetes Care Inc, The Glucose Program LLC, and TypeZero Technologies Inc.
Read More

When was DexCom founded?

DexCom was founded in 1999.

How can I contact DexCom?

DexCom's mailing address is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. The official website for the company is www.dexcom.com. The medical device company can be reached via phone at (858) 200-0200, via email at investorrelations@dexcom.com, or via fax at 858-200-0201.

This page (NASDAQ:DXCM) was last updated on 8/14/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.